Atlas Capital Advisors Inc. Takes $1.01 Million Position in Gilead Sciences, Inc. $GILD

Key Points

• Atlas Capital Advisors opened a new position in Gilead Sciences in Q4, buying 8,234 shares valued at about $1.01 million. Other institutions also added or expanded holdings, and institutional investors now own 83.67% of the stock.
• Gilead reported better-than-expected Q1 results, with EPS of $2.03 versus the $1.91 estimate and revenue of $6.96 billion, up 4.4% year over year. The company also announced a quarterly dividend of $0.82 per share, equal to a 2.6% annualized yield.
• Recent catalysts include positive Phase 3 HIV trial results with Merck and progress in its oncology pipeline, while analysts remain broadly constructive with a Moderate Buy consensus and an average price target of $156.93. At the same time, recent insider sales and stock weakness versus key moving averages suggest some near-term caution.

Atlas Capital Advisors Inc. purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 8,234 shares of the biopharmaceutical company's stock, valued at approximately $1,011,000.

Other large investors have also recently modified their holdings of the company. Quattro Advisors LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $26,000. Ares Financial Consulting LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $28,000. Financial Consulate Inc. increased its position in shares of Gilead Sciences by 85.8% during the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 109 shares during the period. North Star Investment Management Corp. increased its position in shares of Gilead Sciences by 54.8% during the fourth quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 86 shares during the period. Finally, BOCHK Asset Management Ltd acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $31,000. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $125.59 on Monday. The stock has a market capitalization of $155.93 billion, a P/E ratio of 17.11 and a beta of 0.31. The company has a 50-day moving average price of $133.16 and a 200-day moving average price of $134.34. Gilead Sciences, Inc. has a 1 year low of $104.46 and a 1 year high of $157.29. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to analysts' expectations of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business's revenue was up 4.4% on a year-over-year basis. During the same period last year, the company earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050--0.650 EPS. On average, equities research analysts forecast that Gilead Sciences, Inc. will post -0.79 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Monday, June 15th. Gilead Sciences's dividend payout ratio (DPR) is currently 44.69%.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead and Merck reported positive topline Phase 3 results for their once-weekly oral HIV regimen, a potentially important catalyst for Gilead’s HIV franchise and long-term growth. Is Gilead (GILD) One of the Top Large Cap Value Stocks to Buy Now?
• Positive Sentiment: Bernstein reiterated a Buy view on Gilead, and unusual call option activity suggests traders are positioning for upside ahead of additional catalysts. Gilead Sciences (GILD) Gets a Buy from Bernstein
• Positive Sentiment: The company advanced a Phase 2 study of denikitug in difficult-to-treat colorectal cancer, adding another pipeline readout that could broaden Gilead’s oncology prospects. Gilead Advances Denikitug Trial in Tough-to-Treat Colorectal Cancer
• Positive Sentiment: Gilead is donating remdesivir to Uganda to support Ebola response efforts, reinforcing the company’s reputation in infectious disease care and public-health leadership. Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
• Neutral Sentiment: Gilead and the Gilead Foundation announced about $3 million in funding with the National AIDS Memorial for HIV/AIDS education and leadership initiatives, a brand-building effort with limited near-term earnings impact. National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
• Neutral Sentiment: Erste Group slightly lowered its FY2026 earnings estimate for Gilead, but the revision was small and stays close to the broader loss expectations already in place. Gilead Advances Denikitug Trial in Tough-to-Treat Colorectal Cancer
• Negative Sentiment: Recent commentary suggests Gilead’s stock has pulled back from its 50-day and 200-day moving averages, indicating some short-term technical pressure despite the positive pipeline news.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the firm's stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $132.27, for a total transaction of $396,810.00. Following the transaction, the chief financial officer directly owned 173,191 shares of the company's stock, valued at $22,907,973.57. This trade represents a 1.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the transaction, the insider directly owned 125,779 shares in the company, valued at $16,513,524.91. The trade was a 18.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 62,000 shares of company stock worth $8,182,190 over the last three months. 0.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Maxim Group upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $165.00 price objective for the company in a research report on Wednesday, May 20th. Morgan Stanley decreased their price objective on shares of Gilead Sciences from $175.00 to $168.00 in a research report on Friday, May 8th. Truist Financial restated a "buy" rating and issued a $157.00 price target (up from $155.00) on shares of Gilead Sciences in a report on Friday, May 8th. Barclays assumed coverage on shares of Gilead Sciences in a report on Friday, February 20th. They issued an "equal weight" rating and a $155.00 price target for the company. Finally, Rothschild & Co Redburn reduced their price target on shares of Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Twenty-five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $156.93.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.